Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas

International Journal of Cancer

Volumn 133, Issue 11, 2013, Pages 2596-2608

  Niskakoski, Anni ^a   Kaur, Sippy ^a   Renkonen Sinisalo, Laura ^b   Lassus, Heini ^b   Järvinen, Heikki J ^b   Mecklin, Jukka Pekka ^c,d   Bützow, Ralf ^b   Peltomäki, Päivi ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

DNA methylation; LINE1; Lynch syndrome; ovarian cancer; p53

Indexed keywords

B RAF KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53;

ADULT; ARTICLE; BRAF GENE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; ENDOMETRIOID CARCINOMA; FEMALE; GENE FREQUENCY; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MISMATCH REPAIR; MOLECULAR DYNAMICS; ONCOGENE K RAS; OVARY CARCINOMA; PIK3CA GENE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

DNA METHYLATION; LINE1; LYNCH SYNDROME; OVARIAN CANCER; P53;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; FEMALE; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884905090     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28287     Document Type: Article

References (50)

1. Kamangar F, Dores GM, Anderson WF,. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
3. Cho KR, Shih I,. Ovarian cancer. Annu Rev Pathol 2009; 4: 287-313.
4. Kurman RJ, Shih I,. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27: 151-60.
5. Maradeo ME, Cairns P,. Translational application of epigenetic alterations: ovarian cancer as a model. FEBS Lett 2011; 585: 2112-20.
6. Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009; 3: 97-137.
7. Watson P, Butzow R, Lynch HT, et al.; International Collaborative Group on HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82: 223-8.
8. Grindedal EM, Renkonen-Sinisalo L, Vasen H, et al. Survival in women with MMR mutations and ovarian cancer: a multicentre study in lynch syndrome kindreds. J Med Genet 2010; 47: 99-102.
9. Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 2012; 120: 612-18.
10. Ketabi Z, Bartuma K, Bernstein I, et al. Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol 2011; 121: 462-5.
11. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504.
12. Abdel-Rahman WM, Ollikainen M, Kariola R, et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene 2005; 24: 1542-51.
13. Lassus H, Leminen A, Lundin J, et al. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003; 91: 504-12.
14. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191-5.
15. Ollikainen M, Gylling A, Puputti M, et al. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 2007; 121: 915-20.
16. Gylling AH, Nieminen TT, Abdel-Rahman WM, et al. Differential cancer predisposition in lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 2008; 29: 1351-9.
17. Pavicic W, Joensuu EI, Nieminen T, et al. LINE-1 hypomethylation in familial and sporadic cancer. J Mol Med (Berl) 2012; 90: 827-35.
18. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002; 62: 4722-9.
19. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005; 11: 6116-26.
20. Woloszynska-Read A, Zhang W, Yu J, et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011; 17: 2170-80.
21. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-6.
22. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-18.
23. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012; 30: 958-64.
24. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the lynch syndrome. Int J Cancer 2008; 123: 444-9.
25. Kolbe DL, DeLoia JA, Porter-Gill P, et al. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype. PLoS One 2012; 7: e32941.
26. Tapper J, Butzow R, Wahlstrom T, et al. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br J Cancer 1997; 75: 1782-7.
27. Kuo KT, Mao TL, Chen X, et al. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010; 16: 1997-2008.
28. Domanska K, Malander S, Staaf J, et al. Genetic profiles distinguish different types of hereditary ovarian cancer. Oncol Rep 2010; 24: 885-95.
29. Steffensen KD, Waldstrom M, Grove A, et al. Improved classification of epithelial ovarian cancer: results of 3 Danish cohorts. Int J Gynecol Cancer 2011; 21: 1592-600.
30. Godoy H, Mhawech-Fauceglia P, Beck A, et al. Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. Int J Gynecol Pathol 2011; 30: 139-44.
31. Sankila R, Aaltonen LA, Jarvinen HJ, et al. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996; 110: 682-7.
32. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011; 24: 1248-53.
33. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-6.
34. Mayr D, Hirschmann A, Lohrs U, et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006; 103: 883-7.
35. Auner V, Kriegshauser G, Tong D, et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009; 9: 111.
36. Jones S, Wang TL, Kurman RJ, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 2012; 226: 413-20.
37. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41: 664-8.
38. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
39. Rahman M, Nakayama K, Rahman MT, et al. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol 2012; 43: 2197-206.
40. Abe A, Minaguchi T, Ochi H, et al. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum Pathol 2013; 44: 199-207.
41. Pal T, Permuth-Wey J, Kumar A, et al. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res 2008; 14: 6847-54.
42. Aysal A, Karnezis A, Medhi I, et al. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am J Surg Pathol 2012; 36: 163-72.
43. Popat S, Hubner R, Houlston RS,. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18.
44. de Miranda NF, Goudkade D, Jordanova ES, et al. Infiltration of lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases. Clin Cancer Res 2012; 18: 1237-45.
45. Pal T, Permuth-Wey J, Sellers TA,. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer 2008; 113: 733-42.
46. Joensuu EI, Abdel-Rahman WM, Ollikainen M, et al. Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res 2008; 68: 4597-605.
47. Lotsari JE, Gylling A, Abdel-Rahman WM, et al. Breast carcinoma and lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases. Breast Cancer Res 2012; 14: R90.
48. Strathdee G, Appleton K, Illand M, et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001; 158: 1121-7.
49. Ahnen DJ,. The American college of gastroenterology Emily Couric lecture-the adenoma-carcinoma sequence revisited: has the era of genetic tailoring finally arrived? Am J Gastroenterol 2011; 106: 190-8.
50. Offit K, Kauff ND,. Reducing the risk of gynecologic cancer in the lynch syndrome. N Engl J Med 2006; 354: 293-5.